Lei Ji, Zhang Alexander, Deng Hongping, Yang Zhihong, Peters Cole W, Lee Kang M, Wang Zhenjuan, Rosales Ivy A, Rickert Charles G, Markmann James F
Center for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Am J Transplant. 2022 Mar;22(3):966-972. doi: 10.1111/ajt.16875. Epub 2021 Nov 15.
Clinical islet transplantation has relied almost exclusively on intraportal administration of pancreatic islets, as it has been the only consistent approach to achieve robust graft function in human recipients. However, this approach suffers from significant loss of islet mass from a potent immediate blood-mediated inflammatory response (IBMIR) and a hypoxic environment. To avoid these negative aspects of the portal site, we explored an alternative approach in which allogeneic islets were transplanted into the intrapleural space of a non-human primate (NHP), treated with an immunosuppression regimen previously reported to secure routine survival and tolerance to allogeneic islets in NHP. Robust glycemic control and graft survival were achieved for the planned study period of >90 days. Our observations suggest the intrapleural space provides an attractive locale for islet transplantation due to its higher oxygen tension, ability to accommodate large transplant tissue volumes, and a lack of IBMIR-mediated islet damage. Our preliminary results reveal the promise of the intrapleural space as an alternative site for clinical islet transplantation in the treatment of type 1 diabetes.
临床胰岛移植几乎完全依赖于经门静脉输注胰岛,因为这是在人类受者中实现强大移植物功能的唯一可靠方法。然而,这种方法存在明显的胰岛数量损失,原因是强烈的即时血液介导的炎症反应(IBMIR)和缺氧环境。为了避免门静脉部位的这些不利因素,我们探索了一种替代方法,即将同种异体胰岛移植到非人类灵长类动物(NHP)的胸腔内,并采用先前报道的免疫抑制方案进行治疗,以确保NHP对同种异体胰岛的常规存活和耐受。在>90天的计划研究期内实现了稳健的血糖控制和移植物存活。我们的观察结果表明,胸腔内空间因其较高的氧张力、容纳大量移植组织体积的能力以及缺乏IBMIR介导的胰岛损伤,为胰岛移植提供了一个有吸引力的部位。我们的初步结果揭示了胸腔内空间作为1型糖尿病治疗中临床胰岛移植替代部位的前景。